

Conclusions: The combination of gefitinib and capecitabine is feasible at doses 250/1250 in advanced colorectal cancer. The combination appears to have a manageable tolerability profile. It is too early to assess efficacy. IRESSA is a trademark of the AstraZeneca group of companies

701

PUBLICATION

Phase II multi center study of combination therapy with irinotecan and S-1 for metastatic colorectal cancer

Y. Komatsu¹, S. Yuki², K. Kato², S. Kato², M. Nakamura², M. Tateyama³, M. Kudo⁴, H. Akita¹, Y. Sakata⁵, M. Asaka². ¹Hokkaido University, Medical Oncology, Sapporo, Japan; ²Hokkaido University, Gastroenterology, Sapporo, Japan; ³Tomakomai Nisseyou Hospital, Gastroenterology, Sapporo, Japan; ⁴Sapporo Hokuyu Hospital, Gastroenterology, Sapporo, Japan; ⁵Misawa City Hospital, Medical Oncology, Misawa, Japan

Background: The currently first-line chemotherapy for metastatic colorectal cancer is multiple-drug therapy including Irinotecan or Oxaliplatin. On the other hand, the efficacy of oral fluorinated pyrimidine anticancer drugs has recently attracted more attention. The oral fluorinated pyrimidine compound S-1, even when used alone, has been reported to show considerable efficacy, achieving a response rate of 39.5% in patients with colorectal cancer (Shirao K, et al: Cancer). Therefore, we planned to conduct a phase II clinical study of combination therapy with irinotecan and S-1, a new oral anticancer drug of the fluorinated pyrimidine type (Komatsu Y, et al: Jpn J Clin Oncol).

Patients and Methods: The antitumor effect was the primary endpoint, while the safety, progression-free survival time, and median survival time were the secondary endpoints. The subjects were untreated patients with metastatic colorectal cancer aged 20–75 years. Based on the results of our previous phase I/II study in patients with gastric cancer (Komatsu Y, et al: UEGW 2005), the dosage was established in consideration of safety for outpatient therapy. Irinotecan was administered at a dose of 100 mg/m² (on days 1 and 15) as an intravenous infusion over 90 minutes, and oral S-1 (40 mg/m²) was administered after breakfast and dinner and then withdrawn for 2 weeks.

Results: At the time of abstract submission, 30 patients were enrolled in the present study. There were 22 men and 8 women. No other serious adverse reactions occurred (either hematological or non-hematological), and all patients could receive therapy safely on an outpatient basis. Interim analysis suggested excellent results, with a response rate of 60%. Median survival time is not reached yet.

Summary: Combination therapy with Irinotecan and S-1 achieved a high response rate and could be given safely. These findings suggest that the therapy has potential as first-line treatment for metastatic colorectal cancer. And it may be equal to a FOLFIRI treatment for metastatic colorectal cancer. The latest data will be reported at the meeting.

702

PUBLICATION

Cetuximab and irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (AIO) is active and safe in the first-line treatment of metastatic colorectal cancer (mCRC) expressing the epidermal growth factor receptor (EGFR)

G. Folprecht¹, M.P. Lutz², P. Schöffski³, T. Seufferlein⁴, A. Nolting⁵, P. Pollert⁶, C. Köhne⁷. ¹Medizinische Klinik und Poliklinik I, Universitätsklinik, Onkologische Tagesklinik/Ambulante Chemotherapie, Dresden, Germany; ²Caritasklinik St. Theresien, Medical Clinic for Gastroenterology, Saarbrücken, Germany; ³University Hospital Gasthuisberg, Clinic for Medical Oncology, Leuven, Belgium; ⁴Universitätsklinik Ulm, Dept. Oncologie/Haematologie, Ulm, Germany; ⁵Merck KGaA, Dept. Clinical Pharmacology & Pharmacokinetics, Darmstadt, Germany; ⁶Merck KGaA, Dept. Clinical R&D, Clinical Operations Germany, Darmstadt, Germany; ⁷Klinikum Oldenburg gGmbH, Clinic for Oncology/Haematology, Oldenburg, Germany

Background: The AIO schedule of irinotecan/5-FU/FA is highly active in mCRC. Cetuximab (Erbix[®]) is an IgG1 monoclonal antibody, specific for the EGFR, which is active in mCRC. This phase I/II study investigated the safety/tolerability, pharmacokinetics (PK) and activity of cetuximab when added to irinotecan/5-FU/FA (AIO) for the first-line treatment of mCRC.

Materials and Methods: 21 patients with previously untreated, EGFR-expressing mCRC received cetuximab (400 mg/m² initial dose and 250 mg/m²/week, thereafter) and infusional 5-FU (24-h) at two dose levels (1,500 mg/m² [low-5-FU group, n=6] or 2,000 mg/m² [high-5-FU group, n=15]), plus FA at 500 mg/m² and irinotecan at 80 mg/m², weekly x6 q50d. Dose-limiting toxicities (DLTs) were: neutropenia or skin toxicity >grade 3; febrile neutropenia/leucopenia; thrombocytopenia, diarrhoea,

mucositis >grade 2; other relevant organ toxicity >grade 2, each in the first cycle of treatment.

Results: 20 patients were assessable for tolerability in the first cycle. There were 3 DLTs (20%) in the high-5-FU group (diarrhoea grade 3 [n=2] and diarrhoea grade 4 [n=1]) and none in the low-5-FU group. In the high-5-FU group, 7/14 patients (50%) received ≤80% of planned dose during the first cycle due to dose reductions, and treatment delays were required in 10/14 patients. In the low-5-FU group, all 6 patients received >80% of the planned dose. 5 patients had a dose delay of cetuximab during the first cycle (3 due to skin toxicity, 2 due to diarrhoea caused by chemotherapy). Throughout the study, common grade 3/4 adverse events were acne-like rash (38%), diarrhoea (29%) and nausea and vomiting (5%). Most were grade 3 events: only two incidents of grade 4 events were reported (1 grade 4 acne-like rash and 1 diarrhoea). Cetuximab PKs were not affected by chemotherapy, and derived PK parameters were similar in the 2 different 5-FU dose groups. 14/21 assessable patients (67%, 95% CI: 47%–87%) had a response (2 complete and 12 partial responses), and 6 (29%) had stable disease. Median survival (OS) was 33 months. 4 patients received secondary surgery of their liver metastases with curative intent. A fifth was eligible for surgery but declined.

Conclusions: Cetuximab plus weekly infusional 5-FU/FA (AIO) and irinotecan is safe and has demonstrated a promising overall response rate of 67% and median OS of 33 months. A 5-FU dose of 1,500 mg/m² in this combination is recommended for further studies in this setting.

703

PUBLICATION

Phase II multicenter study of capecitabine plus oxaliplatin (XELOX) sequentially followed by capecitabine and irinotecan (XELIRI) in first-line therapy for metastatic colorectal cancer (MCRC)

J. Cassinello¹, J.V. Álvarez², M.J. García-López³, E. Pujol⁴, A. Colmenarejo⁵, F. De Segovia⁶, F. Marcos⁷, E. Filipovich⁸. ¹Hospital General de Guadalajara, Servicio de Oncología Médica, Guadalajara, Spain; ²Hospital Rodríguez Chamorro, Servicio de Oncología Médica, Zamora, Spain; ³Hospital Nuestra Señora de Alarcos, Servicio de Oncología Médica, Ciudad Real, Spain; ⁴Hospital Santa Bárbara, Servicio de Oncología Médica, Soria, Spain; ⁵Hospital Central de la Defensa, Servicio de Oncología Médica, Madrid, Spain; ⁶Hospital Nuestra Señora del Valle, Servicio de Oncología Médica, Madrid, Spain; ⁷Hospital Nuestra Señora del Prado, Servicio de Oncología Médica, Talavera de la Reina, Spain; ⁸Hospital Nuestra Señora de Sonsoles, Servicio de Oncología Médica, Avila, Spain

Background: In phase II trials XELOX or XELIRI shown good antitumor efficacy and tolerability in first-line in MCRC. The aim of this study is to explore the efficacy and safety of XELOX sequentially followed by XELIRI as first-line treatment of MCRC. We want to evaluate specifically the impact of sequential scheduling on the dose-limiting neurotoxicity associated with oxaliplatin accumulation.

Material and Methods: Pts with histological or cytological confirmation of MCRC, ECOG PS ≤2 and adequate bone marrow, renal and hepatic function were included. Prior chemotherapy for MCRC was not allowed. Pts received 4 cycles of XELOX (capecitabine 1000 mg/m² orally bid d1–14 + oxaliplatin 130 mg/m² i.v. d1, q3w) followed by 4 cycles of XELIRI (capecitabine 1000 mg/m² bid d1–14 + irinotecan 240 mg/m² i.v. d1, q3w). This sequential schedule was repeated until unacceptable toxicity or disease progression.

	XELOX		XELIRI	
	Grade2	Grade3	Grade2	Grade3
Neutropenia	6	6	8	8
Anemia	13	3	15	0
Diarrhea	13	6	23	8
Intestinal subocclusion	0	3	0	0
Neurosensory	6	6	8	0
Paresthesia	0	3	0	0
Nausea	13	0	15	0
Vomiting	9	3	23	0
Asthenia	16	3	15	8

Results: Up to date, 33 pts have been enrolled: M/F (70%/30%); median age 69 years (range 41–78); ECOG PS 0–1 (94%). Previous treatment included surgery (81%), adjuvant chemotherapy (33%) and radiotherapy (12%). 169 cycles (median 4, range 1–16) have been administered. During the 1st sequential schedule, 32 pts received XELOX (106 cycles, median 4), and 13 pts received XELIRI (47 cycles, median 4). In the 2nd sequential